Wed Mar 05 23:30:00 UTC 2025: ## Wegovy Price Cut: $150 Savings for Some, But Millions Still Excluded
**New York, NY** – Novo Nordisk announced a price reduction for its popular weight-loss drug, Wegovy, lowering the cost to $499 per month for uninsured or commercially insured patients whose plans don’t cover the medication. This represents a $150 savings compared to the previous coupon price. The move is intended to capture patients who previously relied on cheaper compounded versions of the drug, following the FDA’s recent declaration that the Wegovy shortage is over.
However, the price cut excludes millions of Americans. Patients on Medicare and Medicaid, who often lack coverage for weight-loss drugs, will not benefit from the reduced price and continue to face out-of-pocket costs exceeding $1,300 per month.
Novo Nordisk will distribute the discounted Wegovy through its own online pharmacy, a strategy increasingly adopted by drug manufacturers to control distribution. This mirrors a similar offering from competitor Eli Lilly for its weight-loss drug, Mounjaro.
The timing of the price reduction is significant, coming just weeks before the market for compounded Wegovy, a cheaper alternative, is expected to shrink following FDA action. An estimated two million patients used compounded Wegovy over the past year.
While the price cut could boost Wegovy sales, its impact is limited by the exclusion of government-insured patients, highlighting ongoing concerns about medication affordability and access for large segments of the population.
First Piper 